drugset / Trial / NCT05922813
Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.
RandomizedParallel-groupDouble-blindTreatment
Summary
A phase I clinical trial to evaluate the safety and tolerability of a single-dose administration of BMI2004 Inj. (hyaluronidase, recombinant) in healthy adults
Timeline
- Start
- 2022-06-30
- Primary completion
- 2023-03-10
- Completion
- 2023-04-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMI2004 | Unknown | — | Other |
Indications
No indication recorded.